Live
FierceBiotechGilead's $2.2B Ouro buyout delivers autoimmune T-cell engager, new purpose for GalapagosFierceBiotechAardvark halts trials of obesity candidate, putting entire pipeline on pauseFierceBiotechInnovent sees path to China approval after eye disease drug matches Eylea in phase 3FierceBiotechMerck hands over $20M in IBD drug target deal with Flagship's QuotientCytiva (Google News)Cytiva and Yoshindo advance domestic biosimilar manufacturing in Japan - BioSpectrum AsiaEndpoints NewsApnimed set to exit sleep disorder joint venture with Shionogi for $100M upfrontBioPharma DiveHow former Acorda CEO Ron Cohen landed at a Parkinson’s cell therapy startupAgilentSG Americas Securities LLC Has $109.97 Million Position in Agilent Technologies, Inc. $A - MarketBeatEndpoints NewsGilead bets $1.68B upfront on Ouro Medicines’ autoimmune program, with Galapagos expected to pitch inEndpoints NewsMerck partners with Flagship startup Quotient to search for genetic clues to IBDThermo FisherCommunity Trust & Investment Co. Decreases Stake in Thermo Fisher Scientific Inc. $TMO - MarketBeatThermo FisherCarderock Capital Management Inc. Buys 5,662 Shares of Thermo Fisher Scientific Inc. $TMO - MarketBeat
FierceBiotech Mar 24, 2026

Innovent sees path to China approval after eye disease drug matches Eylea in phase 3

Innovent sees path to China approval after eye disease drug matches Eylea in phase 3

Original
Body unavailable. Use the original source.

Directory

59 All